Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn’s disease

References

• Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30:699–706.
   PubMed Web of Science ®Google Scholar
• Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–266.
   PubMed Web of Science ®Google Scholar
• Hamedani R, Feldman R, Feagan B. Drug development in IBD: budesonide. Aliment Pharmacol Ther. 1997;3:98–107.
   Google Scholar
• Molodecky N, Soon I, Rabi D, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–727.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer S, Van Assche G, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014;8:927–935.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandbron W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.
   PubMed Web of Science ®Google Scholar
• Townsend C, Parker C, MacDonald J, et al. Antibiotics for induction and maintenance of remission in Crohn’s disease. Abstract CDDW. Forthcoming. Cochrane Database. Banff, Alberta, Canada. CDDW Abstracts. Feb.
   Google Scholar
• Hanauer S, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol. 2001;96:635–643.
   PubMed Web of Science ®Google Scholar
• Yang YX, Lichtenstein GR. Corticosteroids in Crohn’s disease. Am J Gastroenterol. 2002;97(4):803–823.
   PubMed Web of Science ®Google Scholar
• Fahey J, Guyre PM, Munck A. Mechanisms of anti-inflammatory actions of glucocorticoids. In: Weissman G, editor. Advances in inflammation research. Vol. 2. New York: Raven Press; 1981. p. 21–51.
   Google Scholar
• Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25(3):451–468.
   PubMed Web of Science ®Google Scholar
• Summers R, Switz D, Sessions J, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847–869.
   PubMed Web of Science ®Google Scholar
• Ford AC, Bernstein CN, Khan KJ, et al. Corticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr;106(4):590–599.
   PubMed Web of Science ®Google Scholar
• Singleton J, Law D, Kelley M, et al. National Cooperative Crohn’s Disease Study: adverse reactions to study drugs. Gastroenterology. 1979;77:870–882.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–630.
   PubMed Web of Science ®Google Scholar
• Brattsand R. Overview of newer glucocorticoid preparations for inflammatory bowel disease. Can J Gastroenterol. 1990;4:407–414.
   Google Scholar
• Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–845.
   PubMed Web of Science ®Google Scholar
• Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn’s disease. Gastroenterology. 1998;115(4):835–840.
   PubMed Web of Science ®Google Scholar
• Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol. 1996;8(9):905–909.
   PubMed Web of Science ®Google Scholar
• Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. The Global Budesonide Study Group. Gut. 1997;41(2):209–214.
   PubMed Web of Science ®Google Scholar
• Escher JC. European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol. 2004;16(1):47–54.
   PubMed Web of Science ®Google Scholar
• Levine A, Weizman Z, Broide E, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr. 2003;36(2):248–252.
   PubMed Web of Science ®Google Scholar
• Pharma DF. Summary of product characteristics for Budenofalk 3mg gastro-resistant capsule. United Kingdom. Dr Falk. Prescribing information. [Cited 2017 Jan 1]
   Google Scholar
• Food and Drug Administration. US labeling for Entocort. [Cited 2017 Jan 1]. United States. FDA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021324s008lbl.pdf
   Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumabd as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• Siegel C, Whitman C, Spiegel B, et al. Development of an index to define overall disease severity in IBD. Gut. 2016.
   PubMedGoogle Scholar
• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–667.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.
   PubMed Web of Science ®Google Scholar
• Khanna R, Bressler B, Levesque B, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386:1825–1834.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Fiorino G, Buisson A, et al. First-line therapy in adult Crohn’s disease: who should receive anti-TNF agents?. Nat Rev Gastroenterol Hepatol. 2013;10:345–351.
   PubMed Web of Science ®Google Scholar
• Yarur A, Strobel S, Deshpande A, et al. Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol. 2011 Oct;7(10):652–659.
   Google Scholar
• Torres J, Mehandru S, Colombel J, et al. Crohn’s disease. Lancet. 2017 Apr 29;389(10080):1741-1755.
   PubMed Web of Science ®Google Scholar
• Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260.
   PubMed Web of Science ®Google Scholar
• Munkhold P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn’s disease in the county of Copenhagen, 1962-1987L a sixfold increase in incidence. Scand J Gastroenterol. 1992;27:609–614.
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62.
   PubMed Web of Science ®Google Scholar
• Lofberg R, Danielsson A, Salde L. Oral budesonide in active Crohn’s disease. Aliment Pharmacol Ther. 1993;7:611–616.
   PubMed Web of Science ®Google Scholar
• Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994;331(13):836–841.
   PubMed Web of Science ®Google Scholar
• Thiesen A, Thomson A. Review article: older systemic and newer topical glucocorticosteroids and the gastrointestinal tract. Aliment Pharmacol Ther. 1996;10:487–496.
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev. 2005;57(2):303–316.
   PubMed Web of Science ®Google Scholar
• Möllmann HW Pharmacological basis for the use of nonsystemic oral and rectal steroids in inflammatory bowel disease. In: Tytgat GNJ, Bartelsman JFM, Van Deventer SJH, editors. Inflammatory bowel diseases. Proceedings of the Falk Symposium No. 85; 1995 Jun 29–Jul 1; Den Haag. Kluwer Academic Publishers, 1995: 633–646
   Google Scholar
• Boumpas DT, Paliogianni F, Anastassiou ED, et al. Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin Exp Rheumatol. 1991;9:413–423.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci. 1993;14:436–441.
   PubMed Web of Science ®Google Scholar
• Johansson S, Andersson K, Brattsand R, et al. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone, dipropionate and prednisolone in man. Eur J Respir Dis Suppl. 1982;122:74–82.
   PubMedGoogle Scholar
• Greenberg G. Budesonide for the treatment of inflammatory bowel disease. Can. J Gastroenterol. 1994;8:369–372.
   Google Scholar
• Tremaine W, Hanauer S, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn’s disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002;97:1748–1754.
   PubMed Web of Science ®Google Scholar
• Edsbacker S, Andersson P, Lindberg C, et al. Liver metabolism of budesonide in rat, mouse and man. Drug Metab Dispos Biol Fate Chem. 1987;15:403–411.
   PubMed Web of Science ®Google Scholar
• Lundin P, Edsbacker S, Bergstrand M, et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn’s disease. Aliment Pharmacol Ther. 2003;85–92.
   PubMed Web of Science ®Google Scholar
• Cvetkovic S, Edsbacker S, Wollmer P, et al. Prolonged release profile of Entocort (budesonide) capsules . Scand J Gastroenterol. 1996;31:6.
   Google Scholar
• Edsbäcker S, Bengtsson B, Larsson P, et al. A pharmacoscintigraphic evaluation of oral budesonide given as controlled release (Entocort™) capsules. Aliment Pharmacol Ther. 2003;17(4):525–536.
   PubMed Web of Science ®Google Scholar
• Edsbacker S, Jonsson S, Lindberg C, et al. Metabolic pathways of the topical glucocorticoid budesonide in man. Drug Metab Dispos. 1983;11(6):590–596.
   Google Scholar
• Edsbäcker S, Andersson T. Pharmacokinetics of budesonide (Entocort™ EC) capsules for Crohn’s disease. Clin Pharmacokinet. 2004;43:803.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Motoya S, Takazoe M, et al. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn’s disease: a multicentre, double-blind, randomized, parallel-group Phase II study. J Crohns Colitis Apr. 2013;7(3):239–247.
   PubMed Web of Science ®Google Scholar
• Rezaie A, Kuenzig M, Benchimol E, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015 Jun;3(6):CD000296.
   Google Scholar
• Thomsen O, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339(6):670–674.
   Web of Science ®Google Scholar
• Tromm A, Bunganič I, Tomsová E, et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s disease. Gastroenterology. 2011 Feb;140(2):425–434.
   PubMed Web of Science ®Google Scholar
• Van Ierssel A, Van der Sluys Veer A, Verspaget H, et al. Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohn’s disease. Aliment Pharmacol Ther. 1995;9(2):173–178.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease. Aliment Pharmacol Ther. 1998;12(5):419–424.
   PubMed Web of Science ®Google Scholar
• Tursi A, Giorgetti G, Brandimarte G, et al. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn’s disease: an open-label, budesonide-controlled, randomized study. Med Sci Monit. 2006;12(6):PI29–32.
   PubMed Web of Science ®Google Scholar
• Kane S, Schoenfeld P, Sandborn W, et al. The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther. 2002;16(8):1509–1517.
   PubMed Web of Science ®Google Scholar
• Kuenzig ME, Rezale A, Seow CH, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD002913.
   PubMed Web of Science ®Google Scholar
• Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996;110(1):45–51.
   PubMed Web of Science ®Google Scholar
• Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn’s disease. A placebo controlled one year study. Gut. 1996;39(1):82–86.
   PubMed Web of Science ®Google Scholar
• Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn’s disease–results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther. 1998;12(2):175–183.
   PubMed Web of Science ®Google Scholar
• Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. Gastroenterology. 1999;116:294–300.
   PubMed Web of Science ®Google Scholar
• Cortot A, Colombel JF, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn’s disease. Gut. 2001;48(2):186–190.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Sandborn WJ, Persson A, et al. Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005;21(4):363–371.
   PubMed Web of Science ®Google Scholar
• Gross V, Andus T, Ecker KW, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease. The Budesonide Study Group. Gut. 1998;42(4):493–496.
   PubMed Web of Science ®Google Scholar
• Ewe K, Bottger T, Buhr H, et al. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicenter randomized placebo-controlled trial. Eur J Gastroentorol Hepatol. 1999;11:277–282.
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Petraki K, Sfakianakis M, et al. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn’s disease. Clin Gastroenterol Hepatol. 2003;1(2):122–128.
   PubMed Web of Science ®Google Scholar
• Schoon E, Bollani S, Mills P, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3(2):113–121.
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn’s disease. Inflamm Bowel Dis. 2009;15(3):375–382.
   PubMed Web of Science ®Google Scholar
• de Jong DJ, Bac DJ, Tan G, et al. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn’s disease in remission. Neth J Med. 2007;65(9):339–345.
   PubMed Web of Science ®Google Scholar
• Seidegård J. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. Clin Pharmacol Ther. 2000;68:13–17.
   PubMed Web of Science ®Google Scholar
• Howde O, Moum BA. Epidemiology and clinical course of Crohn’s disease: results from observational studies. World J Gastroenterol. 2012;18(15):1723–1731.
   PubMed Web of Science ®Google Scholar